Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
- T. Vesikari, D. Matson, Penny M Heaton
- MedicineNew England Journal of Medicine
- 5 January 2006
This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- J. Sadoff, M. le Gars, H. Schuitemaker
- MedicineNew England Journal of Medicine
- 13 January 2021
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate, and systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in thoseWho received the high dose, while reactogenicity was lower after the second dose.
Rotavirus disease and vaccination: impact on genotype diversity.
- J. Matthijnssens, J. Bilcke, M. Van Ranst
- BiologyFuture Microbiology
- 8 December 2009
It appears that the total number of hospitalizations due to rotavirus infections is being reduced, at least in developed countries that implemented a universal immunization program, however, continued surveillance is warranted, especially regarding the long-term effects of the vaccines.
The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region.
- A. Nardone, F. de Ory, E. Miller
- Medicine, BiologyVaccine
- 7 November 2007
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey.
- K. Van Herck, P. van Damme, E. Walker
- MedicineJournal of Travel Medicine
- 2004
The results of this large-scale airport survey clearly demonstrate an important educational need among those traveling to risk destinations and initiatives to improve such education should target all groups of travelers, including business travelers, those visiting friends and relatives, and the elderly.
Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study.
- P. van Damme, C. Giaquinto, F. Huet, L. Gothefors, M. Maxwell, M. van der Wielen
- MedicineJournal of Infectious Diseases
- 1 May 2007
The results of the present study suggest that routine rotavirus vaccination for infants <6 months of age could significantly reduce the substantial burden of this potentially serious childhood disease.
The seroepidemiology of herpes simplex virus type 1 and 2 in Europe
- R. Pebody, N. Andrews, R. Vranckx
- Medicine, Political ScienceSexually Transmitted Infections
- 28 May 2004
There is large variation in the seroepidemiology of herpes simplex virus types 1 and 2 in the general populations of eight European countries, particularly in northern Europe, and the observation that a significant proportion of adolescents are now HSV-1 susceptible may have implications for transmission and clinical presentation.
The global impact of vaccination against hepatitis B: a historical overview.
- A. Zanetti, P. van Damme, D. Shouval
- MedicineVaccine
- 18 November 2008
Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study.
- P. van Damme, C. Giaquinto, M. Maxwell, P. Todd, M. van der Wielen
- MedicineJournal of Infectious Diseases
- 1 May 2007
Rotavirus genotypes G1-G4 and G9 are associated with the majority of RVGE infections in the areas studied, with geographic and seasonal variation in the distributions of rotavirus strains.
Rationale for pertussis booster vaccination throughout life in Europe.
- F. Zepp, U. Heininger, P. van Damme
- MedicineLancet. Infectious Diseases (Print)
- 1 July 2011
...
...